DA Davidson Comments on UiPath Inc.’s Q3 2025 Earnings (NYSE:PATH)

UiPath Inc. (NYSE:PATH) – Analysts at DA Davidson issued their Q3 2025 earnings estimates for shares of UiPath in a report released on Friday, September 6th. DA Davidson analyst G. Luria forecasts that the healthcare company will post earnings per share of ($0.08) for the quarter. DA Davidson currently has a “Neutral” rating and a $15.00 price objective on the stock. The consensus estimate for UiPath’s current full-year earnings is ($0.22) per share.

UiPath (NYSE:PATH) last issued its earnings results on Thursday, September 5th. The healthcare company reported $0.04 earnings per share for the quarter, beating analysts’ consensus estimates of $0.03 by $0.01. The firm had revenue of $316.00 million for the quarter, compared to analysts’ expectations of $303.69 million. UiPath had a negative return on equity of 3.89% and a negative net margin of 8.13%. The firm’s revenue for the quarter was up 10.0% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.09) earnings per share.

Several other equities research analysts also recently issued reports on the stock. Needham & Company LLC reiterated a “hold” rating on shares of UiPath in a research note on Friday. KeyCorp reaffirmed a “sector weight” rating on shares of UiPath in a research report on Thursday, May 30th. Wells Fargo & Company raised their price objective on UiPath from $14.00 to $15.00 and gave the company an “equal weight” rating in a research report on Friday. Evercore ISI upped their target price on UiPath from $13.00 to $16.00 and gave the stock an “in-line” rating in a research report on Friday. Finally, Royal Bank of Canada reiterated a “sector perform” rating and set a $16.00 target price on shares of UiPath in a report on Friday. Sixteen equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. According to data from MarketBeat, UiPath currently has a consensus rating of “Hold” and an average target price of $17.71.

UiPath Stock Performance

Shares of NYSE:PATH opened at $12.19 on Monday. The stock has a 50-day simple moving average of $12.19 and a 200-day simple moving average of $16.54. The stock has a market capitalization of $6.98 billion, a P/E ratio of -76.19 and a beta of 0.87. UiPath has a 1 year low of $10.37 and a 1 year high of $27.87.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of PATH. Vanguard Group Inc. increased its holdings in shares of UiPath by 5.6% in the 1st quarter. Vanguard Group Inc. now owns 40,217,936 shares of the healthcare company’s stock valued at $911,741,000 after acquiring an additional 2,133,078 shares during the last quarter. Norges Bank acquired a new position in shares of UiPath in the 4th quarter valued at about $165,749,000. Pacer Advisors Inc. acquired a new position in shares of UiPath in the 2nd quarter valued at about $69,180,000. Dimensional Fund Advisors LP grew its position in shares of UiPath by 37.2% during the 2nd quarter. Dimensional Fund Advisors LP now owns 2,783,571 shares of the healthcare company’s stock valued at $35,296,000 after buying an additional 754,519 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. raised its stake in UiPath by 4.4% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 2,553,264 shares of the healthcare company’s stock worth $63,423,000 after acquiring an additional 108,013 shares during the period. Institutional investors own 62.50% of the company’s stock.

About UiPath

UiPath Inc provides an end-to-end automation platform that offers a range of robotic process automation (RPA) solutions primarily in the United States, Romania, the United Kingdom, the Netherlands, and internationally. The company offers a suite of interrelated software to build, manage, run, engage, measure, and govern automation within the organization.